To ask the Secretary of State for Health, what comparative assessment he has made of variations in (a) one, (b) five and (c) 10-year survival rates for pancreatic cancer in each (i) region and (ii) clinical commissioning group; and if he will make a statement.
There are some variations in survival rates for pancreatic cancer patients between different countries and different parts of the United Kingdom. We have looked at the international comparisons from EUROCARE 5 – the study of survival and care of cancer patients based on European Cancer Registries - but it can be difficult to interpret survival comparisons for cancers with poor prognosis. Although this only covers patients diagnosed up to 2007, the key issue is that survival rates for pancreatic cancer remain poor – and a challenge to be tackled – across the world.
We await the final report of the independent Cancer Taskforce, which will make recommendations across the whole cancer care pathway.